Literature DB >> 27042493

Comparison of Long-term Complications in Patients on Haemodialysis and Peritoneal Dialysis Longer than 10 Years.

Arzu Ozdemir Kayalar1, Taner Basturk2, Yener Koc2, Figen Yilmaz3, Feyza Bayraktar Caglayan1, Tamer Sakaci4, Elbis Ahbap4, Abdulkadir Ünsal5.   

Abstract

INTRODUCTION: Depending on developments in dialysis techniques and new treatment strategies for comorbid diseases, life expectancy has increased. As a result, dialysis related long term complications could be seen more frequently. We investigated and compared long term complications of the Haemodialysis (HD) and Peritoneal Dialysis (PD) in patients with history if either mode at least 10years.
MATERIALS AND METHODS: A 13HD & 16PD patients were included to the study. Basic demographic parameters and prevalence of cardiovascular diseases (CVD), uraemic peripheral neuropathy (PNP), parathyroid adenoma, parathyroidectomy and acquired cystic disease (ACD) were assessed.
RESULTS: HD patients were older than PD patients (p=0.035) and duration of dialysis was longer in HD patients (p=0.001). CVD was present in 18 patients (9 HD, 9 PD). There was no difference in presence of CVD between HD and PD patients (p=0.455). Valvular diseases (n=15), diastolic dysfunction (n=8), left ventricular hypertrophy (n=5), ischemic heart disease (n=3) and congestive heart failure (n=1) were investigated. Uraemic peripheral neuropathy was observed in 14 of the patients (8 HD, 6 PD patients). Eight patients had mixed type sensory motor neuropathy and 3 patients had mixed type sensorial neuropathy, 2 patients had demyelinating PNP, 1 patient had axonal PNP and 3 of them had CTS related to peripheral neuropathy. Parathyroid adenoma was detected in 4 patients (2 HD, 2 PD) and 3 patients (1 HD, 2 PD) had history of parathyroidectomy. Serum phosphate and iPTH levels were higher in HD patients (p=0.003, p=0.04, respectively). ACD was detected in 14 patients (7 HD, 7 PD). There was no difference between PD and HD patients (p=0.75).
CONCLUSION: HD patients were older than PD patients and had longer duration of dialysis. The prevalence of long term complications was similar in HD and PD modalities. CVD especially valvular diseases were common complication in both modalities.

Entities:  

Keywords:  Acquired cystic disease; Amyloidosis; Cardiovascular disease; Renal osteodystrophy

Year:  2016        PMID: 27042493      PMCID: PMC4800559          DOI: 10.7860/JCDR/2016/15279.7172

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  17 in total

Review 1.  Acquired cystic disease: mechanisms and manifestations.

Authors:  I Ishikawa
Journal:  Semin Nephrol       Date:  1991-11       Impact factor: 5.299

2.  Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome.

Authors:  B Charra; E Calemard; G Laurent
Journal:  Blood Purif       Date:  1988       Impact factor: 2.614

3.  Clinical characteristics and diagnostic considerations in acquired renal cystic disease.

Authors:  N Narasimhan; T A Golper; M Wolfson; M Rahatzad; W M Bennett
Journal:  Kidney Int       Date:  1986-11       Impact factor: 10.612

Review 4.  Amyloidosis and dialysis: pathophysiological aspects.

Authors:  T B Drüeke; J Zingraff; L H Noël; T Bardin; D Kuntz
Journal:  Contrib Nephrol       Date:  1988       Impact factor: 1.580

5.  Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study.

Authors:  Fabio Malberti; Daniele Marcelli; Ferruccio Conte; Aurelio Limido; Donatella Spotti; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2001-06       Impact factor: 10.121

6.  The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002.

Authors:  Robert N Foley; Suying Li; Jiannong Liu; David T Gilbertson; Shu-Cheng Chen; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

7.  Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis.

Authors:  F Gejyo; S Odani; T Yamada; N Honma; H Saito; Y Suzuki; Y Nakagawa; H Kobayashi; Y Maruyama; Y Hirasawa
Journal:  Kidney Int       Date:  1986-09       Impact factor: 10.612

8.  Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.

Authors:  Alfred K Cheung; Mark J Sarnak; Guofen Yan; Michael Berkoben; Robert Heyka; Allen Kaufman; Julia Lewis; Michael Rocco; Robert Toto; David Windus; Daniel Ornt; Andrew S Levey
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

Review 9.  Dialysis-related amyloidosis: importance of biocompatibility and age.

Authors:  M Jadoul
Journal:  Nephrol Dial Transplant       Date:  1998       Impact factor: 5.992

10.  Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.

Authors:  J Craig Longenecker; Josef Coresh; Neil R Powe; Andrew S Levey; Nancy E Fink; Alice Martin; Michael J Klag
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

View more
  3 in total

1.  Frequency of Polyneuropathy in Patients on Long Term Peritoneal Dialysis Treatment.

Authors:  Taner Basturk; Yener Koc; Aarzu Ozdemir Kayalar; Figen Yilmaz; Nuri Baris Hasbal; Tamer Sakaci; Elbis Ahbap; Abdulkadir Unsal
Journal:  J Clin Diagn Res       Date:  2017-06-01

2.  Early prediction of hemodialysis complications employing ensemble techniques.

Authors:  Mai Othman; Ahmed Mustafa Elbasha; Yasmine Salah Naga; Nancy Diaa Moussa
Journal:  Biomed Eng Online       Date:  2022-10-11       Impact factor: 3.903

3.  Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis.

Authors:  Carola Palmerini; Luca Piscitani; Giuseppina Bologna; Chiara Riganti; Paola Lanuti; Domitilla Mandatori; Lorenzo Di Liberato; Giorgia Di Fulvio; Vittorio Sirolli; Giulia Renda; Caterina Pipino; Marco Marchisio; Mario Bonomini; Assunta Pandolfi; Natalia Di Pietro
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.